Related Experiment Video
Updated: Aug 10, 2026
Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
Published on: July 16, 2011
Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA
Andrew Godfrey1, John Anderson, Antigoni Papanastasiou
1Cancer Research United Kingdom Viral Oncology Group, Wolfson Institute for Biomedical Research, UCL, Gower Street, London, United Kingdom WC1E 6BT.
Abstract:
We use lentiviral-delivered RNA interference (RNAi) to inhibit the growth of a model of primary effusion lymphoma (PEL) in vitro and in vivo. RNAi is a phenomenon allowing the sequence-specific targeting and silencing of exogenous and endogenous gene expression and is being applied to inhibit viral replication both in vitro and in vivo. We show that silencing of genes believed to be essential for the Kaposi sarcoma-associated herpesvirus (KSHV) latent life cycle (the oncogenic cluster) has a varied effect in PEL cell lines cultured in vitro, however, concomitant silencing of the viral cyclin (vcyclin) and viral FLICE (Fas-associating protein with death domain-like interleukin-1beta-converting enzyme) inhibitory protein (vFLIP) caused efficient apoptosis in all PEL lines tested. We demonstrate that in a murine model of PEL, lentiviral-mediated RNA interference both inhibits development of ascites and can act as a treatment for established ascites. We also show that the administered lentiviral vectors are essentially limited to the peritoneal cavity, which has advantages for safety and dosage in a therapeutic setting. This shows the use of lentiviral-mediated RNA interference in vivo as a potential therapeutic against a virally driven human cancer.
Insights
RNA interference (RNAi) effectively inhibits primary effusion lymphoma (PEL) growth by silencing essential viral genes. Lentiviral RNAi shows therapeutic potential against this virally driven cancer in vivo.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Primary effusion lymphoma (PEL) is a virally driven cancer associated with Kaposi sarcoma-associated herpesvirus (KSHV).
- RNA interference (RNAi) offers sequence-specific gene silencing for therapeutic applications.
- Targeting KSHV genes is a potential strategy for PEL treatment.
Purpose of the Study:
- To investigate the efficacy of lentiviral-delivered RNA interference (RNAi) against PEL.
- To assess the impact of silencing specific KSHV genes on PEL cell growth and survival.
- To evaluate the therapeutic potential of lentiviral RNAi in a murine model of PEL.
Main Methods:
- Utilized lentiviral vectors for RNA interference (RNAi) delivery.
- Silenced KSHV genes, including viral cyclin (vcyclin) and viral FLICE inhibitory protein (vFLIP), in PEL cell lines in vitro.
- Administered lentiviral RNAi in a murine model of PEL to assess effects on ascites development and established ascites.
- Monitored lentiviral vector biodistribution within the peritoneal cavity.
Main Results:
- Concomitant silencing of vcyclin and vFLIP induced efficient apoptosis in all tested PEL cell lines.
- Lentiviral-mediated RNAi inhibited ascites development and treated established ascites in a murine PEL model.
- Administered lentiviral vectors were primarily confined to the peritoneal cavity, suggesting improved safety and dosage control.
Conclusions:
- Lentiviral-delivered RNA interference targeting specific KSHV genes is effective against PEL in vitro.
- Lentiviral RNAi demonstrates therapeutic efficacy in a murine model of PEL, inhibiting tumor growth and treating ascites.
- The localized delivery of lentiviral vectors offers a promising safety profile for in vivo cancer therapy.
Related Concept Videos
02:15Experimental RNAi
01:30Inhibitors of Viral Protein Synthesis